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Abstract 
Foot-and-mouth disease virus (FMDV) leader protein (Lpro) is a papain-like proteinase, which plays an important role 
in FMDV pathogenesis. Lpro exists as two forms, Lab and Lb, due to translation being initiated from two different start 
codons separated by 84 nucleotides. Lpro self-cleaves from the nascent viral polyprotein precursor as the first mature 
viral protein. In addition to its role as a viral proteinase, Lpro also has the ability to antagonize host antiviral effects. To 
promote FMDV replication, Lpro can suppress host antiviral responses by three different mechanisms: (1) cleavage 
of eukaryotic translation initiation factor 4 γ (eIF4G) to shut off host protein synthesis; (2) inhibition of host innate 
immune responses through restriction of interferon-α/β production; and (3) Lpro can also act as a deubiquitinase and 
catalyze deubiquitination of innate immune signaling molecules. In the light of recent functional and biochemical 
findings regarding Lpro, this review introduces the basic properties of Lpro and the mechanisms by which it antago-
nizes host antiviral responses.
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1 Introduction
Foot-and-mouth disease (FMD) is a highly contagious 
disease caused by foot-and-mouth disease virus (FMDV). 
Outbreaks of FMD spread rapidly and usually cause dev-
astating economic losses and trade embargoes. FMDV 
primarily infects cloven-hoofed animals including cattle, 
swine, sheep, and various ruminants. The virus belongs 
to the genus Aphthovirus in the Picornaviridae family 
and has seven serotypes: O, A, C, SAT1, SAT2, SAT3, and 
Asia1. There is poor cross-protection among these sero-
types [1].
The genome of FMDV consists of a single-stranded 
positive-sense RNA with a length of about 8500 nucleo-
tides. The genomic structure can be artificially divided 
into three parts: the 5′ untranslated region (UTR), the 
open reading frame (ORF), and 3′-UTR. The single long 
ORF of viral RNA encodes a polyprotein that is subse-
quently processed into four mature structural proteins 
(VP1, VP2, VP3, and VP4) which form the capsid, and 
about 12 non-structural proteins (Lpro, 2A, 2B, 2C, 3A, 
3B, 3C, 3D, 3AB or 3ABC, 2BC, and 3CD) (Figure 1) [2].
FMDV leader protein (Lpro) and 3Cpro proteins have 
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ability to inhibit the functions of a variety of host pro-
teins, suppressing cellular immune responses [5–8]. For 
instance, 3Cpro and Lpro can induce the cleavage of host 
eukaryotic translation initiation factor 4 γ (eIF4G), lim-
iting the synthesis of various host proteins [7, 9]. This 
could possibly include type I interferons (IFNs), indi-
rectly promoting viral replication [10]. 3Cpro can also 
cleave the nuclear factor kappa B (NF-κB) essential 
modulator (NEMO) and karyopherin α1 (KPNA1) to 
abate innate immune signaling [5, 6]. Moreover, Lpro can 
directly cleave various other host proteins to suppress 
antiviral responses [11].
Lpro, as a viral proteinase, self-cleaves from the nascent 
viral polyprotein precursor during FMDV infection and 
plays an important role in viral pathogenesis. Lpro has two 
different forms (termed Lab and Lb) due to the initiation 
of translation at two functional AUGs that are separated 
by 84 nucleotides [12]. However, the Lb AUG is more 
efficiently used than the Lab site despite translation initi-
ating from the Lab site [13, 14]. Hence, Lb is more abun-
dant than Lab. The complete loss of Lab-coding region of 
FMDV is reported to be lethal for the virus [15], whereas 
the viruses with precisely deleted Lb coding regions 
(leaderless viruses) were viable and could replicate both 
in cattle and swine. However, these viruses could not 
induce any pathological changes and their replicative 
ability was attenuated [16, 17]. Furthermore, the super-
natants of primary cell cultures infected with leaderless 
viruses possess stronger antiviral activity than the super-
natants from wild-type FMDV-infected cells [18]. Recent 
evidence shows that the nature and extent of the resid-
ual leader protein sequences of FMDV precisely lack-
ing the Lb-coding sequence determine different growth 
characteristics in different host-cell systems [19]. Based 
on these studies, Lpro is thought to have multifunctional 
roles in viral pathogenicity and is considered an impor-
tant virulence factor of FMDV.
Lpro is known to contribute to virus propagation by 
suppressing host antiviral activity [20]. Lpro has an antag-
onistic effect on host antiviral responses via at least three 
mechanisms. The most well-characterized mechanism 
is the cleavage of eIF4G by Lpro, which shuts off host 
cap-dependent mRNA translation, and IFN translation 
may be included [7, 21]. Additionally, Lpro also directly 
Figure 1 Structure of FMDV genome and proteolytic processing of viral polyprotein. The ORF of the viral proteins is displayed in the boxed 
area. The noncoding regions consist of the 5′ UTR and the 3′ UTR with a poly(A) tail. The viral functional elements in the 5′ UTR include the S frag-
ment, the polycytidylic acid region [poly(C)], the pseudoknot structures (PKs), the cis-acting replicative element (cre), and the IRES. The 5′ end of the 
5′ UTR is covalently bound to the viral 3B (or VPg) protein, which is crucial for viral RNA replication.
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suppresses production of IFNs (including type I and 
type III) at the transcriptional level, through disrupting 
the IFN signaling pathway to inhibit host innate immune 
responses [8, 22, 23]. Finally, Lpro can significantly inhibit 
the activation of some signaling transduction molecules 
involved in antiviral pathways through its deubiquit-
ination enzyme (DUB) activity [22]. In this review, we 
discuss the current knowledge of these antagonistic 
mechanisms of Lpro against host antiviral responses.
2  Different forms of FMDV Lpro
FMDV Lpro shows similarities to the members of the 
cysteine proteinase family in structure and function [24]. 
It recognizes the junction sites between Lpro and VP4 and 
then cleaves itself from the polyprotein [4]. This auto-
matic self-processing makes Lpro the first mature viral 
protein during FMDV infection. The two forms of Lpro 
(Lab and Lb) generated have been confirmed in vitro and 
in  vivo [4, 25, 26]. Both these forms of Lpro exhibit the 
same enzymatic properties [27]. Each of them releases 
itself from the polyprotein via intermolecular or intramo-
lecular self-cleavage [4, 25]. It is deemed that intramolec-
ular self-processing is more efficient than intermolecular 
self-processing [28]. Nevertheless, the detailed mecha-
nisms for the production of the two forms of Lpro have 
not been clearly elucidated. The mechanisms for selec-
tion of Lab start site (AUG1) or Lb start site (AUG2) for 
protein synthesis are complex. Through constructing 
synthetic fusion genes of AUG1 and AUG2, Belsham 
determined that before initiation of protein synthesis at 
AUG2, the ribosomes need to scan past AUG1–AUG2. 
The two initiation sites can both be used efficiently, 
whereas internal ribosome entry sites (IRESs) contrib-
ute to a slight biased utilization of the Lb site [29]. In a 
translation system mimicking the translation initiation 
pattern of the FMDV RNA observed during viral infec-
tion, the spacer region between two start codons plays a 
role in start codon recognition and biases the start codon 
selection towards the second one to initiate protein syn-
thesis. The utilization of the first start codon depends 
on its sequence context [30]. Another study showed that 
the selection of AUG2 does not depend on the assembly 
of 48S complex formation on the 5′ side of AUG1 [31]. 
A recent study based on previous work presented by 
Belsham [29] revealed a mechanism involving bias-usage 
of translation initiation sites of Lpro, suggesting that the 
poor nucleotide context of the Lab-initiation site restricts 
its translational efficiency. The ribosomes access the Lb 
site through linear scanning, starting from the upstream 
IRES proximal to the first initiation codon and this is not 
an independent entry process [14]. An early study by 
Poyry et al. suggested an alternative mechanism by which 
a few ribosomes reach the second initiation site [32].
Mutations in the initiation site of Lb disables the pro-
duction of progeny viruses in transfected baby hamster 
kidney (BHK) cells, while mutations in the Lab initia-
tion site do not affect the production of progeny viruses 
[33]. The precise deletion of the Lb from the A12 strain 
of FMDV (serotype A) produced viable viruses in BHK 
cells, while the mutant virus showed a reduced growth 
rate and produced smaller plaques [15]. A recent report 
shows that FMDVs (serotype O) lacking complete Lb 
coding sequences can be obtained in BHK cells by modi-
fying Lab start codons, while the precise deletion of the 
Lb coding region alone prevents FMDV replication in 
primary bovine thyroid cells [19]. In addition, the dele-
tion of the “spacer” region between two initiation codons 
is not lethal for the virus. These findings imply that the 
Lpro sequence is physiologically associated with FMDV 
propagation.
Apart from Lab and Lb, another form of Lpro has been 
observed, which is termed sLbpro or Lb’ [34, 35]. sLbpro is 
generated by the removal of six or seven residues from 
the C-terminal extension (CTE) of Lpro during FMDV 
infection [36]. The trimming of the CTE of Lpro results 
in different characteristics of sLbpro. sLbpro cannot form 
homodimers like Lb via interactions of the CTE of one 
monomer with the substrate-binding site of the neigh-
boring one, and vice versa [34, 35]. The Lb homodimers 
have been observed by X-ray crystallography and nuclear 
magnetic resonance (NMR) [34, 35], providing weak evi-
dence for intermolecular reactions during self-cleavage. 
The X-ray structures of the L protease were obtained 
with the two forms of the protein, Lb (not Lab) and sLb, 
which additionally were modified (C51A). However, 
both the kinetic evidence of cleavage efficiencies and the 
structural evidence provided by NMR study on the mon-
omeric variant of Lb, have strongly indicated an intra-
molecular mechanism of self-processing. Moreover, the 
obvious formation of a homodimer suggests that it may 
have a potential function in the modulation of enzyme 
activity; the dimer may be a physiologically active form 
responsible for the cleavage activities after the self-pro-
cessing [35, 37]. The loss of the last six or seven resi-
dues in the CTE does not affect the cleavage efficiencies 
of sLbpro on the eIF4G site. This is because both Lb and 
sLbpro use residue C133 and two conserved amino acid 
residues (D184 and E186) of CTE, mediating binding and 
cleavage of eIF4GI. However, the cleavage efficiencies 
of Lb and sLbpro are different during the intramolecular 
incision of the polyprotein substrate due to the lack of 
an intact CTE in sLbpro, as the presence of at least one 
intact CTE is more favorable for intermolecular cleavage 
[38]. Although, the exact role of sLbpro remains unknown, 
it is thought to have a function during FMDV infection 
[38]. A putative SAP domain identified in Lpro is also 
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involved in the biological activities and functions of Lpro. 
The mutation in some sites of the SAP domain lead to 
the production of different forms of Lpro; all with varying 
functions [39].
3  Cleavage activity of Lpro
Lpro, the first matured protein of FMDV, self-cleaves from 
the viral genome ORF-encoding polyprotein. The self-
release of Lpro is thought to result from both intramolec-
ular [28] and intermolecular [4] cleavage. The sequences 
of KVQRKLK*GAGQSS at the junction between Lpro and 
viral structural protein precursor (P1-2A) are thought 
to be the cleavage sites [4] (Figure  2A). In addition to 
the self-cleavage activity of Lpro, it can cleave the homo-
logues of host eIF4G in  vitro (Figure  2B). The amino 
acid sequence recognized as the cleavage site of eIF4GI 
is PSFANLG*RTTLST [40], and VPLLNVG*SRRSQP for 
eIF4GII [21]. However, there remain some controversies 
about the precise cleavage sites within eIF4GI and eIF-
4GII generated by the Lbpro, because the cleavage sites 
of eIF4GI or eIF4GII in the virus-infected cells have not 
been identified.
Lpro is a papain-like cysteine proteinase. Although 
sequencing shows that Lpro shares low nucleotide iden-
tity with papain family members [24], the typically con-
served catalytic cysteine and histidine residues belonging 
to papain-like proteinase have been identified in Lpro [41]. 
The catalytic cysteine site is located at the top of the cen-
tral α-helix, and the catalytic histidine site lies opposite 
to it on a turn between two β-sheets in the right-hand 
domain [42]. The most conserved region between 
papain-like proteases and Lb structures surrounds the 
active center, particularly the secondary components, α1 
and β5–β6 [42].
The crystal structure of Lpro (indicating the Lbpro) 
includes a globular domain similar to other members of 
the papain superfamily cysteine proteinase, and a flex-
ible CTE. Lpro also possesses the same overall folding, 
which resembles the cellular prototype of papain. How-
ever, the pro-peptide binding loop and many other loops 
found in papain are not observed in Lpro [42]. Members 
of the papain proteinase superfamily have a correspond-
ing activity unit, which comprises the catalytic triad of 
Cys/His/Asn [43]. This catalytic unit of Cys/His/Asp is 
also present in Lpro. According to a detailed compari-
son of the two active sites, certain hydrogen bonds and 
water molecules localized at the catalytic site are remark-
ably conserved. Hydrogen bonds stabilize the side-chain 
amide group contributing to the oxyanion hole in both 
enzymes. One of the carboxylate oxygen atoms of Asp164 
and amide nitrogen atoms of Asn46 form a hydrogen 
bond in Lb. In papain, the hydrogen bond comprises a 
P-Ser176 hydroxyl group and P-Gln19 amide oxygen 
atom. The multiple discrepancies between the structures 
of Lpro and cysteine protease give rise to physicochemi-
cal differences between the two enzymes. For example, 
in the soluble state, when the concentration of cations 
increases, cysteine protease displays excellent tolerance 
and keeps its original state, whereas the activity of Lpro 
changes markedly. The fluctuation of pH can significantly 
Figure 2 The cleavage activity of Lpro. A The self-cleavage activity of Lpro. Lpro can cleave itself from the viral polyprotein translated from the 
FMDV genome by either an intramolecular or intermolecular reaction. sLbpro is generated by removing six or seven residues from the C terminus of 
Lpro and B schematic representation of eIF4G and PABP cleavage induced by Lpro. Lpro can cleave eIF4G, eIF3, and PABP.
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influence the activity of Lpro because its cleavage activity 
varies greatly in different pH ranges [34].
4  Cleavage of host proteins induced by Lpro
Eukaryotic cellular translation initiation factor 4F (eIF4F) 
is a protein complex that recruits ribosomes to bind to 
host mRNA, initiating cap-dependent translation. This 
recruitment process is a rate-limiting step and there-
fore regulates translation [44]. The eIF4F complex com-
prises eIF4E small cap-binding protein, eIF4G scaffolding 
protein, and eIF4A ATP-dependent RNA helicase with 
capped-mRNA. The cap binding factor eIF4E, can bind 
to a segment of eIF4G to facilitate the formation of the 
eIF4E/cap-mRNA complex. As a core apparatus of eIF4F 
complex, eIF4G is a scaffolding protein that provides the 
binding regions for eIF4E, eIF4A, and RNA elements to 
form the eI4F complex. The eIF4G protein also provides 
binding sites that recruit the small ribosomal subunit 
interacting protein eIF3 (recruiting the 40S ribosomal 
subunits to the 5′-end of the mRNA in eIF4F complex), 
poly(A)-binding protein (PABP), and eIF4E kinases Mnk1 
(mitogen-activated protein kinase signal-integrating 
kinase1) and Mnk2, regulating host mRNA translation 
[45].
eIF4G proteins possess two homologous proteins in 
yeast, eIF4GI (TIF4631) and eIF4GII (TIF4632), sharing 
a similar function. Both of them contain the conserved 
binding sites for eIF4E, PABP, eIF3 and RNA. For eIF4GI, 
it is reported that its N-terminal portion provides the 
binding sites for eIF4E and PABP, whereas eIF4A and 
eIF3 bind to the C-terminal portion of eIF4GI [46, 47]. 
Some picornaviruses including poliovirus, human rhi-
novirus 2, and FMDV can effectively cleave the eIF4GI, 
yielding N- and C-terminal fragments [40, 47]. FMDV 
Lb protease can also cleave eIF4GII, generating a C-ter-
minal fragment [48]. The loss of integrity of eIF4GI and 
eIF4GII blocks the formation of the eIF4F complexes, 
which directly influences the cellular cap-dependent 
translation. However, the C-terminal fragment of both 
eIF4G proteins containing the binding sites for eIF4A 
and eIF3 can still bind to the FMDV IRES as efficiently 
as the non-processing eIF4GI and eIF4GII respectively 
[47, 48]. Studies over the last two decades have shown 
that regulation of host and viral mRNAs by eIF4G is 
achieved by different mechanisms. Viral protein synthesis 
initiated at two distinct sites from artificial fusion genes 
is independent of the cap-binding eIF4F complex in the 
presence of IRES [29]. Furthermore, the cleavage prod-
ucts of eIF4GI (C-terminal portion) stimulate the trans-
lation of uncapped RNAs and those carrying IRESs [49]. 
The interaction of the two eIF4G proteins with IRES is 
an essential event for promoting IRES activity. Therefore, 
viral RNA translation is unaffected [48, 50].
eIF4GI is a major form of eIF4G, which correlates with 
inhibition of cellular cap-dependent protein synthesis 
within FMDV-infected cells [4, 40]. However, cellular 
protein synthesis can still be maintained at a reduced 
level, with the complete loss of intact eIF4GI when virus 
replication is inhibited [51]. The discovery of human eIF-
4GII, which appears functionally analogous to eIF4GI, 
has resolved this puzzle [52]. The shut-off of host cell 
protein synthesis significantly decreases the expression of 
various cytokines and the major histocompatibility com-
plex (MHC), resulting in delayed host antiviral effects. 
However, viral uncapped RNA can be translated through 
an IRES that is independent of intact eIF4G [53]. There-
fore, the virus quickly takes over the host machinery to 
propagate vast numbers of progeny. FMDV lacking Lpro 
is unable to escape the antiviral response and is not dis-
seminated in the infected animals [16].
Apart from the cleavage of eIF4G, Lpro can cleave a 
series of cellular proteins, such as eIF3a, polypyrimi-
dine tract-binding protein (PTB), PABP and Gemin5, 
which are involved in the control of translation, and 
death domain associated protein (Daxx), a key factor 
that crosslinks the apoptosis, innate immune responses 
and transcription control, to interfere with various cel-
lular pathways during viral infection [54]. The events 
associated with the extent of cytopathic effects in FMDV-
infected cells are proteolysis of PTB, which is involved 
in mRNA stability and RNA localization, interaction 
of PABP with the entire FMDV 3′-UTR, and the bind-
ing of two subunits of eIF3 (eIF3a and b) with the IRES 
[11]. Recently, Piñeiro et al. [54] reported that the RNA-
binding protein Gemin5 is also a target of Lpro. Gemin5 
is the RNA-binding factor of a large macromolecule of 
the survival of motor neuron (SMN) complex, which acts 
as a down-regulator of cellular mRNA translation and 
IRES-driven translation initiation [55]. Lpro recognizes 
the sequence RKAR of Gemin5 and induce its proteoly-
sis, yielding two stable products of molecular weight 85 
and 57  kDa within FMDV-infected cells [54]. Daxx has 
also been identified as a substrate of Lpro, and the RRLR 
motif is the recognition site. Daxx is a ligand of Fas, act-
ing as a multifunctional adaptor protein in the process of 
apoptosis, innate immune responses, and in transcrip-
tional regulation [56]. The cleavage recognition site for 
Lpro in PABP1 has not been identified experimentally. The 
sequence similarity with other Lpro substrates and the 
molecular weight of the proteolysis product imply this 
characteristic [11], and it is deduced that a novel motif 
containing sequence (R)(R/K)(L/A)(R) is a putative tar-
get sequence of Lpro. Hence, neuroguidin, an eIF4E and 
cytoplasmic polyadenylation element binding protein 
(CPEB) that plays an important role in neuronal develop-
ment [57], is hypothesized to be a potential target of Lpro, 
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with the target sequence as AKRRALS [54]. Furthermore, 
eIF3a and b are essential to the assembly of the transla-
tion initiation complex, and are associated with PABP 
and RNA-binding protein PTB. This is involved in mRNA 
stability and RNA localization and can be proteolysed by 
FMDV Lpro, whereas PABP can be partial cleaved by Lpro 
[11]. All these studies suggest that Lpro can cleave various 
host proteins and has potential multifunctional roles.
Other than these identified substrates of Lpro, various 
IRES-binding factors that are targets of other picornavi-
rus proteases may contribute to understanding the link 
between these proteins and Lpro. These factors include 
poly(rC)-binding protein 2, Gemin3 (RNA helicase that is 
a component of the SMN complex), RIG-I (retinoic acid-
inducible gene 1; a cytoplasmic RNA helicase that senses 
viral infection), MAVS (mitochondrial antiviral-signaling 
protein), TRIF (Toll/interleukin (IL)-1 receptor domain-
containing adaptor inducing IFN-β or innate immune 
adaptor molecules), and the stress granules protein G3BP 
[58–62].
5  Suppression of IFN production mediated by Lpro
FMDV infection triggers the activation of various pat-
tern recognition receptors (PRRs) and induces a series of 
antiviral responses; with the transcription factor NF-κB 
acting as a sensor in response to the general alteration of 
the cellular environment. After the PRRs recognize the 
pathogens, the coordinated activation of various tran-
scription factors including NF-κB, IFN regulatory factor 
(IRF)3 and IRF7, are initiated to induce early expression 
of type I IFNs and activate host antiviral responses [63].
PRR-induced signal transduction can activate NF-κB 
to translocate into the nucleus through degradation of 
NF-κB inhibitor. Nuclear translocation of NF-κB is fol-
lowed by its binding to the promoter sequences of many 
genes to initiate their transcription. The expression of 
various cytokine genes such as the proinflammatory 
factors, chemokines, and adherence factors is greatly 
enhanced to induce antiviral responses [64, 65]. NF-κB 
also promotes secretion of IFN-α/β and their bind-
ing to corresponding receptors. This activates the JAK/
STAT signaling pathway, which subsequently induces 
the expression of hundreds of IFN-α/β-stimulated genes 
(ISGs). ISGs are a class of antiviral genes that directly 
encode antiviral proteins that suppress virus propagation 
at different stages of the viral replication cycle [66]. It was 
recently reported that the enhanced expression of ISGs 
increases antiviral effects on FMDV [67]. IRFs are tran-
scription factors that are pivotal for inducing activation 
of IFN-α/β during virus infection; IRF3 and IRF7 are cru-
cial for virus-triggered IFN-α/β secretion [68]. IFN-α/β 
belong to the family of type I IFNs and serve as the first 
line of host defenses, displaying critical antiviral activity 
[69]. In addition, IFN-λ, a type III IFN, possesses IFN-like 
activity and is suggested to be a potent antiviral factor 
that is effective against many viruses [70, 71].
FMDV Lpro acts as an antagonist of innate immune 
responses mainly eliciting the IFN-α/β specific antiviral 
activity at both protein and mRNA levels. The down-reg-
ulation of IFN expression at least in part corresponds to 
the cleavage of eIF4G by Lpro. Both genetically engineered 
FMDV lacking Lpro (A12-LLV2) and wild-type FMDV 
(A12-IC) were observed to induce the production of IFN-
α/β mRNAs in secondary cells from susceptible animals. 
However, the A12-LLV2 mutant induces greater antivi-
ral activity than the wild type as a consequence of failing 
to shut off the expression of host cell protein, including 
IFN-α/β [18]. Lpro, blocks IFN protein synthesis, as well 
as synthesis of IFN-β mRNA and at least three ISGs 
mRNAs [10], including double-stranded RNA-depend-
ent protein kinase (PKR) which plays an important role 
in inhibition of FDMV replication, 2′, 5′ oligoadenylate 
synthetase 1 (OAS1) and myxovirus resistance protein 
1 (Mx1). Using microarray technology, a transcriptional 
profile associated with the antiviral responses against 
FMDV was systematically analyzed. The results suggested 
that Lpro significantly inhibits NF-κB-dependent gene 
expression including expression of IFN-β and ISGs dur-
ing FMDV infection [72]. Furthermore, it was found that 
during the acute infection phase, levels of type I IFN in 
the serum from infected animals significantly increased 
[73]. These studies indicate that type I IFN production is 
associated with antiviral effects against FMDV infection 
and is important in antiviral immune regulation. Lpro as a 
critical virulence factor of FMDV is capable of using mul-
tiple strategies to suppress the production of IFNs.
Many picornaviruses have evolutionarily developed 
subtle strategies that target host factors to subvert IFNs 
signaling pathways, and survive and replicate in host 
cells. For example, enterovirus 2Apro counteracts IFNs 
responses in infected cells by cleaving melanoma differ-
entiation-associated protein 5 (MDA5) and MAVs [74], 
while the mengovirus utilizes Lpro to prevent the produc-
tion of IFN-α/β by inactivating iron/ferritin-mediated 
activation of NF-κB [75]. Cardiovirus Lpro induces cellu-
lar nuclear transport inhibition by binding to a key traf-
ficking regulator RanGTPase [76].
Accumulating evidence shows that Lpro of FMDV 
inhibits IFN production through interfering with the IFN 
signaling pathways. De Los Santos et al. determined that 
Lpro can restrict the induction of IFN-β mRNA [10]. The 
restriction is partially built on the control of transcrip-
tion factors and their upstream signaling factors by Lpro. 
Lpro was shown to be associated with the downregulation 
of nuclear p65/RelA during FMDV infection [8]. P65/
RelA is the core component of NF-κB, and a decrease 
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in the integrity of p65/RelA may lead to the reduction 
of NF-κB. This ultimately results in downregulation of 
IFN-β expression and attenuation of host innate immune 
responses [8]. The mechanism involved in the down-
regulation of p65/RelA induced by Lpro remains unclear. 
Whether the disappearance of p65/RelA is mediated by 
the cleavage activity of Lpro has not been confirmed, since 
no cleavage products of p65/RelA have been determined 
and no cleavage sites have been mapped until now. Wang 
et al. observed that Lpro decreases IRF-3-induced IFN-α/β 
expression by reducing IRF-3 and IRF-7 expression [77]. 
Lpro can also suppress the secretion of IFN-λ1 by disrupt-
ing the IRFs and NF-κB activation, which is crucial for 
IFN-λ1 expression [23]. The strategy adopted by Lpro is to 
cut off the connection between the IFN promoters and 
transcription factors by decreasing the number of tran-
scription factors, thereby inactivating IFN transcription. 
Lpro can also use its deubiquitination activity to prevent 
IFN-α/β production by reducing ubiquitination of several 
type I IFN signaling molecules (details in next section). 
All these results indicate that Lpro uses various strategies 
to suppress IFN-α/β production and promote FMDV 
replication.
6  Deubiquitination activity of Lpro
It is well known that the activation of many signaling events 
that connect the sensors with the transcription factors are 
regulated by ubiquitination enzymes. The conjunction of 
ubiquitin with the signaling molecules contributes to the 
activation of several of these signaling events [66, 78]. How-
ever, there are also deubiquitinating enzymes (DUBs) [79] 
that can inactivate this complex by cleaving ubiquitin from 
its substrate proteins [80]. DUBs belong to the proteinase 
superfamily, of which 100 members have been identified in 
humans. DUBs can be classified into two main categories, 
metalloproteases and cysteine proteases [79]. The DUBs 
such as, A20, cylindromatosis (CYLD) protein, and deubiq-
uitinating enzyme A (DUBA) negatively regulate the ubiq-
uitination process, and hence, are key regulators in antiviral 
responses. For example, A20 is involved in downregulation 
of NF-κB activation, negatively regulating host antiviral 
responses. A20 is a DUB that can remove K63-linked ubiq-
uitin from the ubiquitinated receptor-interacting protein 
(RIP) [80]. RIP is a serine/threonine kinase that contains a 
death domain which can interact with the death receptors 
Fas and tumor necrosis factor (TNF) receptor 1 to mediate 
activation of NF-κB [81]. Deubiquitination of RIP directly 
abates activation of the NF-κB signaling pathway [80]. 
Yokota et al. recently reported that measles virus P protein 
upregulates A20 to repress Toll-like receptors, inhibiting 
activation of NF-κB [82].
Bioinformatics analysis suggests that Lb has a poten-
tial DUB structure and conserved DUB catalytic residues 
(Cys51 and His148). The observed catalytic residues 
are highly conserved in the Lb of all seven serotypes of 
FMDV. Structural analysis indicates that Lb possesses a 
topology similar to DUB ubiquitin-specific 14 and resem-
bles papain-like protease (PLpro) of severe acute respira-
tory syndrome coronavirus (SARS-CoV) [22, 83]. It has 
been observed that mutation of the SAP box (I83A/
L86A) or the catalytically active site (C51A or D163  N/
D164 N) of Lb results in the inactivation of DUB activity 
of Lpro [22].
7  Lpro counteracts innate immune responses 
through its DUB activity
Over the course of long-term evolutionary processes, 
many viruses have developed sophisticated strategies 
to antagonize host antiviral responses. Redirecting the 
cellular ubiquitination system to suppress innate anti-
viral immune signaling pathways is one of the strate-
gies. For example, rotavirus NSP1 blocks NF-κB- and 
IRF- dependent transcription of type I IFN by inducing 
proteasome-mediated degradation of IRF3/5/7 or inhib-
iting IκB-α (inhibitor of NF-κB) degradation to prevent 
NF-κB activation [84, 85]. The accessory proteins, Viral 
Protein R and Virion Infectivity Factor of HIV can inde-
pendently hijack the cellular ubiquitination system to 
decrease IRF-3 expression through proteasomal degrada-
tion and promote virus replication [86]. As a result, the 
production of host antiviral ISGs and proinflammatory 
factors is reduced and the antiviral innate responses are 
attenuated. Moreover, many viruses can hijack host ubiq-
uitination systems to facilitate viral evasion, genomic 
replication, and exocytosis [87].
In addition to hijacking the host ubiquitination system 
for virus replication, many viruses have also developed 
the ability to disrupt cellular ubiquitination machinery to 
terminate or block several signaling transduction path-
ways responsible for the induction of antiviral responses 
[88]. So far, the PLpro of several coronaviruses such as, 
porcine epidemic diarrhea virus, SARS-CoV, and Mid-
dle East respiratory syndrome (MERS-CoV) have been 
shown to possess deubiquitination activity that antago-
nizes IFN production, indicating that PLpro is a multi-
functional protein [89, 90]. Similarly, FMDV Lpro is a 
papain-like protease that acts as an antagonist of IFN by 
negatively regulating IFN transcription and IFN mRNA 
translation [8, 18, 42, 77].
A recent study from Wang et al. has identified a DUB-
like activity of Lb of FMDV [22]. It was observed that 
Lb significantly inhibited ubiquitination of several adap-
tor signaling molecules of type I IFN pathway, includ-
ing RIG-I, TBK1, TRAF3, and TRAF6 (Figure  3). The 
results of sequence alignment and structural bioinfor-
matics analyses indicate that Lpro and ubiquitin-specific 
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protease (USP)14 share similar topology [91]. The DUB 
activity of Lb was further confirmed through observation 
of the inhibitory effects of Lb on ubiquitination of RIG-
I, TRAF3, TRAF6, and TBK1, which eventually prevents 
activation of the type I IFN pathway. This DUB activity 
can be abrogated through mutation of the conserved cat-
alytic sites of Lb. The deubiquitinating processes medi-
ated by Lb are similar to those mediated by DUBA and 
CYLD. Future studies should focus on whether the DUB 
activity of Lb is involved in the signaling pathways regu-
lated by A20.
8  A putative SAP domain identified in Lpro
De Los Santos et al. discovered that FMDV Lpro contains 
a putative SAP domain (scaffold-attachment factor (SAF)
A and SAFB, apoptotic chromatin-condensation inducer 
in the nucleus (ACINUS), and protein inhibitor of acti-
vated STAT (PIAS) domain) [39]. SAP is a conserved 
domain which usually exists in the eukaryotic proteins 
and involved in nucleic acid binding, DNA metabolism, 
DNA repair, chromosomal organization, apoptosis, tran-
scriptional regulation, and immune regulation [92].
SMART software analysis of FMDV Lpro predicted an 
SAP domain between amino acids 47 and 83 of Lb. This 
putative SAP domain in Lpro shows >80% amino acid 
homology with other SAP domains of eukaryotic pro-
teins. Three-dimensional analysis indicates that Lpro and 
the eukaryotic cellular SAP domains share almost the 
same α-helix-turn-α-helix structure, in which only two 
amino acid insertions found in the two α-helices of Lpro 
differed from other cellular SAP domains [39]. Further-
more, a motif of IQKL sequence in Lpro resembles the 
LXXLL signature motif that is mostly found in the SAP 
domain of PIAS. All these observations demonstrate the 
presence of a putative SAP domain in Lpro.
The eukaryotic SAP domain is usually implicated in 
PIAS-associated functions. The SAP motif in PIAS has 
been conserved in evolution, from yeast to humans, and 
this functional motif can recognize and bind to the AT-
rich sequence of scaffold/matrix attachment regions (S/
MARs) of eukaryotic chromosomes. S/MAR is usually 
located close to the enhancer sequence so that it pro-
vides a special microenvironment for transcription [93]. 
PIAS is a negative regulator in host antiviral immunity. 
Figure 3 DUB activity of Lpro in innate immune signaling pathways. Lpro can deubiquitinate several adaptor proteins including RIG-I, TRAF3, 
TRAF6, and TBK1. Deubiquitination of these proteins contributes to the attenuation of host innate immune responses.
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For instance, pias gene knockout mice show more 
resistance to bacterial infection and improved antiviral 
responses to vesicular stomatitis virus. It is proposed 
that PIAS affects the expression of >60 genes, most of 
which are cytokine-induced and pathogen-activated 
genes involved in NF-κB and STAT signaling pathways. 
PIAS1 and PIASy are key proteins of the PIAS family 
and act as inhibitors to negatively regulate NF-κB- and 
STAT-dependent gene expression [94]. Furthermore, 
PIASy adopts distinctive mechanisms to inhibit virus-
induced and IFN-stimulated transcription [95]. Intrigu-
ingly, some viral proteins are localized in the S/MAR 
regions, suggesting an interaction between viral pro-
teins and that S/MAR may block host antiviral activi-
ties [96]. In addition, there is evidence showing that 
the VP35 protein of Ebola virus utilizes PIAS to pro-
mote sumoylation of IRF7, thus contributing to inhibi-
tion of IFN production in immune cells [97]. Until now, 
whether Lpro can adopt an analogous way of using PIAS 
in inhibiting cellular antiviral activities remains unclear. 
However, the N-terminal portion of PIAS3 containing 
the SAP domain was verified to block the NF-κB activa-
tion through binding to the p65/RelA subunit of NF-κB 
[98], whether Lpro can use this manner to interrupt acti-
vation of NF-κB remains unclear.
9  The SAP domain is important for Lpro activity
Zhu et al. found that expression of various IFN-inducible 
genes, chemokines or transcription factors, especially 
NF-κB-dependent gene expression in Lpro SAP domain 
mutant FMDV-infected bovine cells was significantly 
enhanced compared with the wild-type FMDV-infected 
cells [72]. De los Santos and his co-workers revealed that 
SAP domain is a determinant for Lpro nuclear subcellu-
lar localization. In FMDV-infected cells, Lpro progres-
sively translocates to the nucleus, whereas mutation of 
two residues at positions 55 and 58 of Lpro (SAP mutant) 
significantly prevents nuclear translocation of Lpro with-
out affecting the cleavage of eIF4G. This suggests that the 
SAP domain affects retention of Lpro in the nucleus within 
the FMDV-infected cells. The proper subcellular locali-
zation of Lpro in the nucleus is deemed to mediate the 
Lpro-dependent degradation of p65/RelA. Observations 
concerning SAP-related cellular antiviral responses sug-
gest that in SAP-mutant FMDV-infected cells, the mRNA 
expression levels of several NF-κB-dependent cytokines, 
chemokines, and ISGs are higher than in wild-type 
FMDV-infected cells [39]. Collectively, the aforemen-
tioned results demonstrate that subcellular localization 
of Lpro in the nucleus is an important factor in the sup-
pression of innate immune responses, and that the SAP 
domain is involved in this process. Besides, a recent study 
demonstrated that the catalytic activity and SAP domain 
of Lpro were required for suppressing poly(I:C)-induced 
IFN-λ1 production [23].
Diaz-San Segundo et  al. found that inoculation of 
pigs with SAP-mutant FMDV (I55A and L58A muta-
tions were introduced in Lpro) can induce early pro-
tection against FMD [99]. No clinical signs of FMD, 
viremia, or virus shedding were observed, even when 
the pigs were inoculated at 100-fold higher doses than 
those required to cause clinical signs with wild-type 
FMDV. The SAP-mutant FMDV elicited strong adap-
tive immune responses that provided complete protec-
tion against wild-type FMDV infection. Impressively, 
the neutralizing antibody response was induced as 
early as 2 days post-inoculation and lasted for at least 
21  days after inoculation. In the blood of pigs inocu-
lated with SAP mutant virus, expression of IFN-α, 
TNF-α, IL-1, and IL-6 was higher than in pigs inocu-
lated with the wild-type virus. Zhu et al. reported that 
FMDV manipulates ubiquitin-activating enzyme one to 
promote viral replication, and the SAP domain of Lpro 
was involved in this process, which indicates that SAP 
maybe has a novel role [100]. All these studies suggest 
that FMDV Lpro plays an important role in virus repli-
cation process, and the SAP domain may be a critical 
region for the maintenance of the biological activities 
of Lpro.
10  Conclusions
FMDV has evolved numerous strategies to evade host 
antiviral responses. In order to survive and replicate 
in host cells, the virus has developed various ways to 
impair or suppress the induction and activation of anti-
viral responses, utilizing viral nonstructural proteins. 
Lpro and 3Cpro are the main viral factors that antagonize 
host immune responses, with Lpro being one of the most 
well-characterized proteins. Lpro can cleave numerous 
host proteins, inhibit cellular protein expression, and 
deubiquitinate some crucial molecules that are essential 
for the activation of antiviral pathways and signal trans-
duction. Intensive study of FMDV Lpro has uncovered 
several mechanisms by which FMDV replicates in host 
cells and suppresses host antiviral responses utilizing Lpro 
(Table 1). However, these observations represent only the 
“tip of the iceberg” and several questions regarding the 
different forms of Lpro and the pathways involved in Lpro-
mediated antagonistic effects need to be answered. Fur-
ther studies are necessary to elucidate these unanswered 
questions and the multifunctional role of Lpro in FMDV 
infection.
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